Spectrum Antimicrobials
Spectrum Antimicrobials is a private pharmaceutical company developing Tri-Ion™ precision chemistries for infection control. It commercializes FDA-cleared Spectricept™ wound-care and hand-hygiene devices while advancing a preclinical pipeline of antimicrobial drug candidates.
- Company typePrivate
- Founded2018
- HeadquartersPetaluma, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Spectrum Antimicrobials does
Spectrum Antimicrobials, Inc. is a privately held pharmaceutical and medical device company founded in 2018 and headquartered in Petaluma, California. The company develops precision chemistries for infection control, built around its proprietary Tri-Ion™ Chemistry platform — a technology derived from screening more than 900 distinct chemistries that converts naturally occurring proteins into antimicrobial agents active against bacteria, viruses, fungi, and spores. Its commercial portfolio includes Spectricept™ Skin and Wound Cleanser (FDA 510(k)-cleared for U.S. prescription and over-the-counter markets) and Spectricept™ Hand Sanitizer (approved for sale within the UK National Health Service hospital system). The company also operates a preclinical drug-candidate pipeline led by SPC-02, a "weaponized protein" therapeutic with claimed efficacy 4,000 times that of conventional HOCl, intended for upper and lower respiratory infections, wound care, and urinary tract infections.
Spectrum manufactures its products in a 14,000 sq. ft. FDA-registered cGMP facility in Petaluma that supports both device production and dedicated R&D. The company generates revenue primarily through sales of FDA-cleared medical devices distributed via direct enterprise sales to U.S. healthcare providers and prescription/OTC channels, alongside B2B sales into the UK NHS. The drug-candidate pipeline remains preclinical and is explicitly not a current revenue source; pricing is not publicly disclosed, with inquiries directed to a sales email and a planned e-commerce channel referenced on the company website.
The company is led by founders Hoji Alimi (Chairman & CEO), Bill Watson (Executive VP of Strategic Business Alliances), Mohammad Esmaeili (VP Engineering & Chemistry R&D), and Stephanie Alimi (Senior Director of Operations). As of the February 2026 SEC filing, Spectrum has raised approximately $26.4 million from 247 accredited investors through an ongoing $35 million Rule 506(c) exempt equity offering. No institutional venture capital or private equity backing is evident in available disclosures, and an estimated $2 million of offering proceeds are earmarked for payments to executive officers, directors, or promoters.
Spectrum Antimicrobials firmographics
Firmographics- Name
- Spectrum Antimicrobials
- Legal name
- Spectrum Antimicrobials, Inc.
- Website
- https://spectrumantimicrobials.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Spectrum Antimicrobials is a private pharmaceutical company developing Tri-Ion™ precision chemistries for infection control. It commercializes FDA-cleared Spectricept™ wound-care and hand-hygiene devices while advancing a preclinical pipeline of antimicrobial drug candidates.
- Ownership category
- akta.pro rank
Spectrum Antimicrobials industry classification
Industry- Product category
- Antimicrobial Pharmaceuticals & Medical Devices
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
- akta.pro secondary industry
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
Keywords
Where Spectrum Antimicrobials is headquartered
LocationHeadquarters
- HQ city
- Petaluma
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Spectrum Antimicrobials business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales
Revenue model
- Medical Device Sales: Sale of FDA-cleared medical devices including Spectricept™ Skin and Wound Cleanser (prescription and OTC markets) and Spectricept™ Hand Sanitizer (UK NHS). Products are distributed through direct sales and potentially e-commerce channels.
- Therapeutic Drug Candidates: Future revenue potential from drug candidates in development for treatment of upper and lower respiratory infections, wound care, and urinary tract infections (UTIs). Products currently in early development stages, not yet approved or commercialized.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Spectrum Antimicrobials product offering
Product offeringCore offering
Spectrum Antimicrobials develops and manufactures precision antimicrobial chemistries for the control, prevention, and treatment of infection. Its commercial offering includes FDA-cleared medical devices (Spectricept™ Skin and Wound Cleanser Rx and Spectricept™ Hand Sanitizer) built on the proprietary Tri-Ion™ Chemistry platform, and it is developing proteomics-based drug candidates (SPC-02) targeting respiratory, wound, and urinary tract infections.
Product overview
Spectrum Antimicrobials is a science-driven pharmaceutical company advancing precision chemistries for infection control. The company operates a unified product portfolio built on its proprietary Tri-Ion™ chemistry platform, which includes FDA-cleared medical devices (Spectricept™ Skin and Wound Cleanser Rx) and a pipeline of proteomics-based drug candidates (SPC-02). The Tri-Ion™ technology converts naturally occurring proteins into therapeutic agents effective against antibiotic-resistant bacteria, viruses, fungi, and spores, with demonstrated stability in challenging clinical environments including high-protein and biofilm conditions.
Differentiator
Problem solved
Functional benefit
Brands
- Spectricept Rx: Spectricept Skin and Wound Cleanser Rx featuring Tri-Ion Chemistry for wound care and infection control.
Products and services
- Spectricept™ Skin and Wound Cleanser Rx FDA-cleared hypochlorous acid-based skin and wound cleanser featuring proprietary Tri-Ion™ Chemistry for infection control in wound care applications; sold through US prescription and OTC markets and available via the company's sales channel.
- Spectricept™ Hand Sanitizer Hand sanitizer product utilizing Tri-Ion™ Chemistry for antimicrobial efficacy, approved for sale within the UK National Health Service hospital system for infection control.
Quantifiable outcome
- 4,000X greater efficacy than conventional HOCl for SPC-02 drug candidate
- +3 more outcomes
Companies that use Spectrum Antimicrobials
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Spectrum Antimicrobials technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Spectrum Antimicrobials partnerships and signals
Strategic signalScale indicators6 records
Recent moves7 records
Expansion highlights6 records
Spectrum Antimicrobials competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Spectrum Antimicrobials social profiles
Digital presenceSpectrum Antimicrobials compliance and trust
Trust signalCompliance3 records
Spectrum Antimicrobials financial estimates
Financial estimateRevenue estimate
Valuation estimate
Spectrum Antimicrobials leadership team
Management profileNumber of profiles
Profiles10 records
Spectrum Antimicrobials funding detail
Funding detailFunding overview
Funding rounds4 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Spectrum Antimicrobials M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Spectrum Antimicrobials
What does Spectrum Antimicrobials do?
Spectrum Antimicrobials develops and manufactures precision antimicrobial chemistries for the control, prevention, and treatment of infection. Its commercial offering includes FDA-cleared medical devices (Spectricept™ Skin and Wound Cleanser Rx and Spectricept™ Hand Sanitizer) built on the proprietary Tri-Ion™ Chemistry platform, and it is developing proteomics-based drug candidates (SPC-02) targeting respiratory, wound, and urinary tract infections.
Is Spectrum Antimicrobials a public or private company?
Spectrum Antimicrobials is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Spectrum Antimicrobials founded?
Spectrum Antimicrobials was founded in 2018. It employs 11 to 50 people.
Where is Spectrum Antimicrobials based?
Spectrum Antimicrobials is headquartered in Petaluma, United States, in the North America region.
How does Spectrum Antimicrobials make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are therapeutic Drug Candidates.
Does Spectrum Antimicrobials have an API?
No public API is recorded for Spectrum Antimicrobials.
What industry is Spectrum Antimicrobials in?
Spectrum Antimicrobials's product category is Antimicrobial Pharmaceuticals & Medical Devices. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 3254 and its SIC code is 2834.